Hepatology communications · 2026
Rapamycin-modified novel tolerogenic dendritic cells induce liver graft tolerance through MHC-II+CD8+ regulatory T cells.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Lin, Zhao Yang, Wang Jing, Chen Qing, Jia Ya-Nan, Pan Li-Chao, Wang Han-Xuan, Yang Hong-Wei, He Qiang, Li Xian-Liang, Lang Ren, Du Guo-Sheng
Аннотация
BACKGROUND: Inducing transplant tolerance to achieve long-term graft survival without immunosuppression remains a central objective in liver transplantation.
METHODS: Using a rat liver transplantation model, we evaluated the effects of infusing rapamycin-modified tolerogenic dendritic cells (Rapa-tolDCs) on graft survival and tolerance induction. Underlying molecular and cellular mechanisms were investigated through activation and inhibition experiments to assess the generation, signaling pathways, and suppressive functions of regulatory T and B cell populations.
RESULTS: Infusion of Rapa-tolDCs induced donor-specific tolerance and markedly prolonged graft survival (median survival time of 65 days, maximum of 102 days). Mechanistically, Rapa-tolDCs, characterized by low expression of Siglec1 and Spp1, functioned independently of the PI3K-mTOR pathway and promoted the differentiation and proliferation of CD8+CD45RClow/- regulatory T cells (CD8+CD45RClow/- Tregs). We identified that these Tregs acquired MHC-II molecules from donor cells via trogocytosis, becoming immune chimeric cells that predominantly secreted interleukin-10 (IL-10) to mediate immune suppression. The generation of these MHC-II+CD8+ Tregs was regulated by the Wnt5a/Fzd4/RhoD signaling axis. Furthermore, elevated levels of Foxp3+ Tregs and IL-10+ Bregs were found to contribute to prolonged graft survival following Rapa-tolDC infusion.
CONCLUSIONS: These findings delineate a complete mechanistic pathway from cell therapy to donor-specific tolerance and provide a foundational strategy for clinical tolerance induction and post-transplant immunomodulation.
METHODS: Using a rat liver transplantation model, we evaluated the effects of infusing rapamycin-modified tolerogenic dendritic cells (Rapa-tolDCs) on graft survival and tolerance induction. Underlying molecular and cellular mechanisms were investigated through activation and inhibition experiments to assess the generation, signaling pathways, and suppressive functions of regulatory T and B cell populations.
RESULTS: Infusion of Rapa-tolDCs induced donor-specific tolerance and markedly prolonged graft survival (median survival time of 65 days, maximum of 102 days). Mechanistically, Rapa-tolDCs, characterized by low expression of Siglec1 and Spp1, functioned independently of the PI3K-mTOR pathway and promoted the differentiation and proliferation of CD8+CD45RClow/- regulatory T cells (CD8+CD45RClow/- Tregs). We identified that these Tregs acquired MHC-II molecules from donor cells via trogocytosis, becoming immune chimeric cells that predominantly secreted interleukin-10 (IL-10) to mediate immune suppression. The generation of these MHC-II+CD8+ Tregs was regulated by the Wnt5a/Fzd4/RhoD signaling axis. Furthermore, elevated levels of Foxp3+ Tregs and IL-10+ Bregs were found to contribute to prolonged graft survival following Rapa-tolDC infusion.
CONCLUSIONS: These findings delineate a complete mechanistic pathway from cell therapy to donor-specific tolerance and provide a foundational strategy for clinical tolerance induction and post-transplant immunomodulation.